Navigation Links
ADVENTRX Requests Meeting with FDA to Discuss ANX-514 Study
Date:12/15/2010

SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) to schedule a meeting for the purpose of discussing its product candidate ANX-514 (docetaxel emulsion for injection). The FDA is expected to set the meeting date within 60 days of receiving the request from ADVENTRX.

"We have performed an extensive analysis of the data from our bioequivalence study of ANX-514, as well as on results from other trials using Taxotere®, and plan to discuss our findings at the meeting," said Brian M. Culley, Chief Executive Officer of ADVENTRX.  

"Based in part on the substantial variability observed with Taxotere as reported in the literature, we believe the transitory elevations in total docetaxel concentrations for ANX-514 do not affect adversely its safety or efficacy relative to Taxotere. However, the FDA is the final arbiter of safety and efficacy and, following our meeting, we will provide an update on the next steps and requirements for advancing ANX514 toward an NDA submission," Mr. Culley continued.  

About ANX-514

ANX-514 is a novel emulsion formulation of the chemotherapy drug docetaxel, a formulation of which is marketed under the brand name Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is being developed to reduce the incidence and severity of side effects associated with detergents, such as hypersensitivity reactions.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use.  More information can be found on the Company's web site at

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Reports Third Quarter Financial Results
2. ADVENTRX to Present at the Wall Street Analyst Forum 21st Annual Institutional Investor Conference on November 11
3. ADVENTRX Submits Exelbine™ New Drug Application
4. ADVENTRX to Participate in Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
5. Reminder: ADVENTRX Presents Today at the Lippert/Heilshorn Life Sciences & MedTech Virtual Conference
6. ADVENTRX Announces 9-Month Stability Data Results for ANX-530
7. ADVENTRX Added to Russell Microcap Index
8. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on May 17
9. ADVENTRX Pharmaceuticals Announces Closing of Financing
10. ADVENTRX Reverse Split Effective; Trading on Adjusted Basis Begins Today
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Randomized Study Presented at ACOG 2009 Annual Meeting Confirming ... cohosh has been widely used in Europe and also ... flashes, night sweats, occasional irritability and mood swings. While ... question of liver safety has arisen in a few ...
... REDWOOD CITY, Calif., May 5 AcelRx Pharmaceuticals, ... Phase 2 clinical trial of its ARX-01 Sufentanil ... candidate being developed for management of acute post-operative ... objective of this open-label study is to assess ...
Cached Medicine Technology:No Causality Found Between Black Cohosh and Liver Problems 2AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System 2AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System 3
(Date:4/23/2014)... Society for Radiation Oncology (ASTRO) has issued a ... for Endometrial Cancer: An ASTRO Evidence-Based Guideline," that ... the treatment of endometrial cancer. The guideline,s executive ... of Practical Radiation Oncology (PRO), the ... guideline is available as an open-access article online ...
(Date:4/23/2014)... has long been considered to be between 180 and ... used refined microscopic techniques that indicate a much smaller ... tract is only as large as a normal studio ... which passes from the mouth through the esophagus and ... 5 meters in a normal adult, and is built ...
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... Parents and physicians concerned about an increase in ... can breathe a sigh of relief. According to a ... years worth of data from states with and without ... to increased use among adolescents. The study is published ... of Adolescent Health . , "Any time a ...
(Date:4/23/2014)... Getting to the bottom of Alzheimer,s disease has ... turns and controversies. In the latest crook in ... insight into the interaction between proteins associated with ... journal ACS Chemical Neuroscience , could have ... K. Surewicz, Krzysztof Nieznanski and colleagues explain that ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2
... one of the biggest controversies in fetal surgery and ... medicine physicians// around the world: What's the best way ... most common conditions requiring fetal surgery and the leading ... NIH-funded study on TTTS, conducted at 17 centers in ...
... a gift that brought tears to the receiver and to ... dollars was pledged to the staff at Toronto’s Hospital for Sick ... scion of a beer baron and well-established friend of the hospital. ... Management mutual fund company and his wife Sonia, have pledged this ...
... A child of seven years has succumbed to the flu, in British ... as it usually peaks in the months of December and January. ... say experts. ,According to Dr. Theresa Tam of the Public ... because of influenza and in a bad year that can go up ...
... fewer infection and death rates is announced by the NHS ... tried out successfully in United States. This announcement was received ... ,The incentive scheme initially is set for heart treatments, ... case of very sick patients and severe complications, the hospitals ...
... Cancer is a complex and common disease caused by ... ,Recent research shows that the constitutional mutation in PALB2 ... ,Previous studies have shown that genes are responsible ... of breast cancer. The two major familial breast cancer ...
... Using a unique weaving machine of their design, Duke ... "scaffold" that could greatly improve the ability of physicians ... cells. ,"If further experiments are successful, ... three or four years," said Franklin Moutos, a graduate ...
Cached Medicine News:Health News:Timeliness, a Critical Factor in Treating TTTS 2Health News:Timeliness, a Critical Factor in Treating TTTS 3Health News:Record Donation to Children’s Hospita 2Health News:Flu Strikes Late - Child Succumbs 2Health News:Mutation In PALB2 Elevates Risk of Cancer 2Health News:Woven Cartilage 2
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
The ADx system uses fluorescence polarization immunoassay technology for the detection of abused drugs and toxicology assays....
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
...
Medicine Products: